Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation
- 1 December 2001
- journal article
- clinical trial
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 28 (11) , 1013-1018
- https://doi.org/10.1038/sj.bmt.1703264
Abstract
Bone Marrow Transplantation is a high quality, peer-reviewed journal covering all aspects of clinical and basic haemopoietic stem cell transplantation.Keywords
This publication has 12 references indexed in Scilit:
- Plasma Concentration Monitoring of BusulfanClinical Pharmacokinetics, 2000
- An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic diseaseBone Marrow Transplantation, 2000
- Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: Incidence, risk factors, and outcomeTransplantation and Cellular Therapy, 1999
- Therapeutic Monitoring of Busulfan in Hematopoietic Stem Cell TransplantationTherapeutic Drug Monitoring, 1998
- An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in childrenBone Marrow Transplantation, 1997
- Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantationClinical Pharmacology & Therapeutics, 1993
- Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacologyCancer Chemotherapy and Pharmacology, 1991
- Busulfan disposition in childrenBlood, 1990
- Pharmacokinetics of high-dose busulfan in childrenCancer Chemotherapy and Pharmacology, 1989
- Regimen-related toxicity in patients undergoing bone marrow transplantation.Journal of Clinical Oncology, 1988